World's Best Scientists 2026 revealed!
Giovanni Palladini

Giovanni Palladini

D-Index & Metrics

Medicine

D-Index
80
Citations
24794
World Ranking
17061
National Ranking
685

Giovanni Palladini publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Giovanni Palladini sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 400 publications — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Giovanni Palladini D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Giovanni Palladini sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Giovanni Palladini is affiliated with the University of Pavia in Italy and has a substantial body of work in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. The scientist's research primarily covers the subfields of Molecular Biology, Genetics, Hematology, Nephrology, and Oncology.

The main topics addressed in Palladini's work include:

  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Parathyroid Disorders and Treatments
  • Multiple Myeloma Research and Treatments
  • Drug Transport and Resistance Mechanisms
  • Peptidase Inhibition and Analysis
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Chronic Myeloid Leukemia Treatments

Frequent collaborators in Palladini's research include Giampaolo Merlini, Paolo Milani, Mario Nuvolone, Efstathios Kastritis, and Stefan Schönland.

The scientist has published extensively in several venues, notably:

  • Blood
  • Amyloid
  • HemaSphere
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)

Several recent publications by Giovanni Palladini demonstrate a focus on amyloidosis and associated therapies. Selected papers include:

  • Management of AL amyloidosis in 2020, 2020, Blood
  • Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA, 2020, Blood

Other significant work in related fields includes:

  • Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis, 2021, New England Journal of Medicine
  • Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis, 2020, Journal of Clinical Oncology
  • A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis, 2020, Blood

Best Publications

  • Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

    Julian D. Gillmore;Mathew S. Maurer;Rodney H. Falk;Giampaolo Merlini

  • New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

    Giovanni Palladini;Angela Dispenzieri;Morie A. Gertz;Shaji Kumar

  • Systemic Cardiac Amyloidoses Disease Profiles and Clinical Courses of the 3 Main Types

    Claudio Rapezzi;Giampaolo Merlini;Candida C. Quarta;Letizia Riva

  • Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis

    Giovanni Palladini;Carlo Campana;Catherine Klersy;Alessandra Balduini

  • A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

    Giovanni Palladini;Ute Hegenbart;Paolo Milani;Christoph Kimmich

  • Systemic immunoglobulin light chain amyloidosis.

    Giampaolo Merlini;Angela Dispenzieri;Vaishali Sanchorawala;Stefan O. Schönland

  • A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

    Ashutosh D. Wechalekar;Stefan O. Schonland;Efstathios Kastritis;Julian D. Gillmore

  • Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

    Giovanni Palladini;Vittorio Perfetti;Laura Obici;Riccardo Caccialanza

  • Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

    R. L. Comenzo;D. Reece;G. Palladini;D. Seldin

  • Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

    Efstathios Kastritis;Giovanni Palladini;Monique C. Minnema;Ashutosh D. Wechalekar

  • A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.

    Giovanni Palladini;Sajitha Sachchithanantham;Paolo Milani;Julian Gillmore

  • Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL

    Giovanni Palladini;Francesca Lavatelli;Francesca Lavatelli;Francesca Lavatelli;Paola Russo;Paola Russo;Paola Russo;Stefano Perlini;Stefano Perlini;Stefano Perlini

  • Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis

    Efstathios Kastritis;Ashutosh D. Wechalekar;Meletios A. Dimopoulos;Giampaolo Merlini

  • Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

    Giovanni Palladini;Paola Russo;Tiziana Bosoni;Laura Verga

  • Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.

    Claudio Rapezzi;Candida Cristina Quarta;Laura Obici;Federico Perfetto

  • Clinical aspects of systemic amyloid diseases.

    Laura Obici;Vittorio Perfetti;Giovanni Palladini;Remigio Moratti

  • Systemic light chain amyloidosis: an update for treating physicians.

    Giampaolo Merlini;Ashutosh D. Wechalekar;Giovanni Palladini

  • The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

    Giada Bianchi;Laura Oliva;Paolo Cascio;Niccolò Pengo

  • The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis

    Giovanni Palladini;Alessandra Barassi;Catherine Klersy;Rosana Pacciolla

  • The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

    Giovanni Palladini;Vittorio Perfetti;Stefano Perlini;Laura Obici

Frequent Co-Authors

Catherine Klersy
Catherine Klersy University of Pavia
Anthony D. Ho
Anthony D. Ho University Hospital Heidelberg
Marco Paulli
Marco Paulli University of Pavia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering Medicine in the USA opens doors to a wide range of related healthcare degrees and career options that can be pursued online. Many students explore fields such as pharmacy, health information management, medical billing and coding, and advanced nursing to complement or broaden their opportunities in healthcare.

For those interested in pharmaceutical care, an online pharmacy school cost is a crucial factor to consider. Online programs can make this advanced degree more accessible and affordable. If you’re drawn to health data and technology, a him degree online can prepare you for key roles in health information management.

Alternatively, earning a medical coding certification is a practical choice for those seeking fast career entry and flexible remote work. Ambitious nurses can pursue leadership and advanced clinical positions by enrolling in one of the most affordable nurse practitioner programs online.

Exploring these pathways enables students to tailor their medical careers, whether seeking clinical roles or supporting the healthcare system in other essential ways.

Best Scientists Citing Giovanni Palladini

Trending Scientists

Recently Published Articles